325 results on '"Amiral, Jean"'
Search Results
2. Anti-Thrombin IgA in a Patient with Multiple Myeloma Leading to In Vitro Interference in Multiple Coagulation Tests and Confounding Diagnosis
3. Generation and pathogenicity of autoantibodies associated to thrombosis and hemostasis
4. Spotlight on the current perspectives on applications of human blood cell culture and organoids: Introductory remarks
5. Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients?
6. Update on Mechanisms, Pathogenicity, Heterogeneity of Presentation, and Laboratory Diagnosis of Heparin-Induced Thrombocytopenia
7. Annexin A1 Is Associated with Adverse Clinical Outcomes in Patients with COVID-19
8. Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes
9. Hemostatic Effects of Tranexamic Acid in Cesarean Delivery: An Ancillary Study of the TRAAP2 Study
10. Vaccine induced thrombotic thrombocytopenia: development and reactivity of anti-platelet factor 4 antibodies and immune pathogenic mechanisms
11. Iodoacetamide blank compensation in FXIII functional assays: Is it still necessary?
12. Anti–protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis
13. Update on Mechanisms, Pathogenicity, Heterogeneity of Presentation, and Laboratory Diagnosis of Heparin-Induced Thrombocytopenia
14. Editorial for the Special Issue of Monitoring Anticoagulants
15. Extra cellular vesicles in blood circulation as biomarkers and messengers of patho-hysiological activity and alterations
16. L’OPÉRATION « CONCORDIA », OU L’ÉPREUVE DU RÉEL
17. Development of IgG, IgM, and IgA Autoantibodies Against Angiotensin Converting Enzyme 2 in Patients with COVID-19
18. Evaluation of Immunostimulatory Potential of Branded and US-Generic Enoxaparins in an In Vitro Human Immune System Model
19. Serological features of antibodies to protamine inducing thrombocytopenia and thrombosis
20. Quantitative measurement of APC-Resistant factor V clotting activity (FV-Leiden) and potential graduation of the associated thrombo-embolic risk
21. Optimization of Heparin Monitoring with Anti-FXa Assays and the Impact of Dextran Sulfate for Measuring All Drug Activity
22. Applying index of circulating anticoagulant to mixing tests with lupus anticoagulant screen and confirm reagents can distinguish with high specificity between lupus anticoagulants and direct factor Xa inhibitors
23. An Optimized and Standardized Rapid Flow Cytometry Functional Method for Heparin-Induced Thrombocytopenia
24. Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants
25. Optimization of Heparin Monitoring with Anti-FXa Assays and Impact of Dextran Sulfate for Measuring All In-Vivo Drug Activity
26. Monitoring plasma levels of factor Xa inhibitors: how, why and when?
27. Development of IgG, IgM, and IgA Autoantibodies Against Angiotensin Converting Enzyme 2 in Patients with COVID-19.
28. Role of Heparin-Dependent Antigens in Immune Heparin-Induced Thrombocytopenia
29. Measurement of blood activation markers applied to the early diagnosis of cardiovascular alterations
30. Mechanisms Involved in Heparin-Induced Thrombocytopenia and Associated Thrombosis
31. Heparin-Dependent Antigens in Heparin-Induced Thrombocytopenia
32. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells
33. Antiphospholipid antibodies before and after liver transplantation
34. Preoperative screening for von Willebrand disease type 1: Low yield and limited ability to predict bleeding
35. Decision Analysis for Use of Platelet Aggregation Test, Carbon 14–Serotonin Release Assay, and Heparin–Platelet Factor 4 Enzyme-Linked Immunosorbent Assay for Diagnosis of Heparin-lnduced Thrombocytopenia
36. Regulation of Adhesion Molecules during Human Endotoxemia: No Acute Effects of Aspirin
37. Revisiting the activated protein C-protein S-thrombomodulin ternary pathway: Impact of new understanding on its laboratory investigation
38. Evaluation of a flow cytometer-based functional assay using platelet-rich plasma in the diagnosis of heparin-induced thrombocytopenia
39. A very potent factor V inhibitor interferes with the levels of all coagulation factors and causes a fatal hemorrhagic syndrome
40. The contact system at the crossroads of various key patho- physiological functions: Update on present understanding, laboratory exploration and future perspectives
41. An update on evidence based diagnostic and confirmatory testing strategies for heparin induced thrombocytopenia using combined immunological and functional assays
42. Evaluation of a New, Rapid, and Quantitative D-Dimer Test in Patients with Suspected Pulmonary Embolism
43. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery
44. Evaluation of a New Rapid D-Dimer Assay for Clinically Suspected Deep Venous Thrombosis (Liatest D-Dimer)
45. Hyperhomocyst(e)inemia and Endothelial Dysfunction in IDDM
46. Hyperhomocyst(e)inemia and Endothelial Dysfunction in IDDM
47. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium
48. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease
49. Circulating endothelial cell/leucocyte adhesion molecules in ischaemic heart disease
50. Direct and reversible inhibition of platelet factor 4 on megakaryocyte development from CD34 sup + cord blood cells: comparative studies with transforming growth factor beta 1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.